A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL-40/Interleukin-13 Receptor α2 Axis.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
12 2021
Historique:
received: 09 11 2020
accepted: 27 05 2021
pubmed: 10 6 2021
medline: 19 1 2022
entrez: 9 6 2021
Statut: ppublish

Résumé

Macrophages mediate inflammation, angiogenesis, and tissue destruction in giant cell arteritis (GCA). Serum levels of the macrophage-associated protein YKL-40 (chitinase 3-like protein 1), previously linked to angiogenesis and tissue remodeling, remain elevated in GCA despite glucocorticoid treatment. This study was undertaken to investigate the contribution of YKL-40 to vasculopathy in GCA. Immunohistochemistry was performed on GCA temporal artery biopsy specimens (n = 12) and aortas (n = 10) for detection of YKL-40, its receptor interleukin-13 receptor α2 (IL-13Rα2), macrophage markers PU.1 and CD206, and the tissue-destructive protein matrix metalloproteinase 9 (MMP-9). Ten noninflamed temporal artery biopsy specimens served as controls. In vitro experiments with granulocyte-macrophage colony-stimulating factor (GM-CSF)- or macrophage colony-stimulating factor (M-CSF)-skewed monocyte-derived macrophages were conducted to study the dynamics of YKL-40 production. Next, small interfering RNA-mediated knockdown of YKL-40 in GM-CSF-skewed macrophages was performed to study its effect on MMP-9 production. Finally, the angiogenic potential of YKL-40 was investigated by tube formation experiments using human microvascular endothelial cells (HMVECs). YKL-40 was abundantly expressed by a CD206+MMP-9+ macrophage subset in inflamed temporal arteries and aortas. GM-CSF-skewed macrophages from GCA patients, but not healthy controls, released significantly higher levels of YKL-40 compared to M-CSF-skewed macrophages (P = 0.039). In inflamed temporal arteries, IL-13Rα2 was expressed by macrophages and endothelial cells. Functionally, knockdown of YKL-40 led to a 10-50% reduction in MMP-9 production by macrophages, whereas exposure of HMVECS to YKL-40 led to significantly increased tube formation. In GCA, a GM-CSF-skewed, CD206+MMP-9+ macrophage subset expresses high levels of YKL-40 which may stimulate tissue destruction and angiogenesis through IL-13Rα2 signaling. Targeting YKL-40 or GM-CSF may inhibit macrophages that are currently insufficiently suppressed by glucocorticoids.

Identifiants

pubmed: 34105308
doi: 10.1002/art.41887
pmc: PMC9298326
doi:

Substances chimiques

CHI3L1 protein, human 0
Chitinase-3-Like Protein 1 0
Interleukin-13 Receptor alpha2 Subunit 0
Macrophage Colony-Stimulating Factor 81627-83-0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2327-2337

Subventions

Organisme : Abel Tasman Talent Program
Organisme : ReumaNederland
ID : 14-3-401

Informations de copyright

© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Exp Mol Med. 2009 Apr 30;41(4):259-68
pubmed: 19299915
Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii22-ii31
pubmed: 29982780
Circ Res. 2018 Aug 31;123(6):700-715
pubmed: 29970365
FASEB J. 2017 Oct;31(10):4370-4381
pubmed: 28637652
Ann Intern Med. 1994 Oct 1;121(7):484-91
pubmed: 8067646
Int J Cancer. 2012 Jul 15;131(2):377-86
pubmed: 21866546
J Biol Chem. 2011 Apr 29;286(17):15332-43
pubmed: 21385870
Structure. 2010 Mar 10;18(3):332-42
pubmed: 20223216
Genes Cells. 2003 Jun;8(6):515-23
pubmed: 12786942
J Allergy Clin Immunol. 2014 Oct;134(4):975-8.e5
pubmed: 24954262
Blood. 2006 Apr 15;107(8):3221-8
pubmed: 16357325
Autoimmun Rev. 2017 Aug;16(8):833-844
pubmed: 28564617
Circulation. 2002 Sep 24;106(13):1664-71
pubmed: 12270860
J Leukoc Biol. 2015 Dec;98(6):931-6
pubmed: 26310833
Am J Pathol. 1999 Sep;155(3):765-74
pubmed: 10487834
J Leukoc Biol. 2014 May;95(5):797-808
pubmed: 24399840
BMC Immunol. 2010 Jun 21;11:30
pubmed: 20565954
Sci Rep. 2017 Jul 26;7(1):6553
pubmed: 28747747
Mol Cancer Ther. 2011 May;10(5):742-51
pubmed: 21357475
Nat Med. 2006 Jan;12(1):99-106
pubmed: 16327802
Oncogene. 2009 Dec 17;28(50):4456-68
pubmed: 19767768
Arthritis Rheum. 2003 Dec;48(12):3522-31
pubmed: 14674004
Mod Pathol. 2017 Jun;30(6):788-796
pubmed: 28256573
Clin Transl Immunology. 2020 Aug 27;9(9):e1164
pubmed: 32884747
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
J Transl Med. 2018 Dec 20;16(1):369
pubmed: 30572904
Allergy. 2018 Aug;73(8):1673-1685
pubmed: 29405354
Arthritis Rheumatol. 2014 Jul;66(7):1927-38
pubmed: 24623536
Am J Respir Crit Care Med. 2010 Sep 15;182(6):805-18
pubmed: 20522789
Sci Rep. 2020 Jan 23;10(1):1017
pubmed: 31974500
Eur J Immunol. 2018 Aug;48(8):1329-1335
pubmed: 29677387
Respir Res. 2015 Dec 22;16:154
pubmed: 26696093
J Leukoc Biol. 2011 Oct;90(4):761-9
pubmed: 21742938
Arthritis Rheumatol. 2019 Aug;71(8):1329-1338
pubmed: 30835950
Rheumatology (Oxford). 2019 Feb 25;:
pubmed: 30805622
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4596-4605
pubmed: 31675076
Rheumatology (Oxford). 2018 Oct 1;57(10):1795-1801
pubmed: 29961816
Circulation. 2010 Feb 23;121(7):906-15
pubmed: 20142449
Arthritis Rheum. 1999 Dec;42(12):2624-30
pubmed: 10616010
Rheumatology (Oxford). 2018 Jun 1;57(6):982-986
pubmed: 29529280
Toxicol Appl Pharmacol. 2012 Apr 1;260(1):89-94
pubmed: 22326992
Medicine (Baltimore). 2004 Nov;83(6):335-341
pubmed: 15525845
Cell Rep. 2013 Aug 29;4(4):830-41
pubmed: 23972995

Auteurs

Yannick van Sleen (Y)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

William F Jiemy (WF)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands, and, UCSI University, Kuala Lumpur, Malaysia.

Sarah Pringle (S)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Kornelis S M van der Geest (KSM)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Wayel H Abdulahad (WH)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Maria Sandovici (M)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Elisabeth Brouwer (E)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Peter Heeringa (P)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Annemieke M H Boots (AMH)

University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH